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Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic 
remissions in all phases of chronic myeloid leukemia (CML). Despite the high effi cacy, relapses 
have been observed and are much more prevalent in patients with advanced disease. The most 
common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. 
Several strategies have been developed to overcome the problem of imatinib resistance, including 
imatinib dose escalation, novel targeted agents and combination treatments. A second generation 
of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl 
and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) 
is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase 
inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes 
imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in 
CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients 
in chronic and accelerated phases, post imatinib failure.
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Ph-positive chronic myeloid leukemia
Chronic myeloid leukaemia (CML) is a rare disease. Although its incidence is low, 
the prevalence of CML is increasing. In the US, the annual incidence of CML is 
1.5 cases/100,000 adults, accounting for 15% of all of the forms of diagnosed leukemia 
(Ries et al 2004).
CML is one of the most extensively studied and, arguably, best understood 
neoplasms. CML is the fi rst malignant disease for which a direct gene link has been 
found and there has been much recent progress in the understanding of the biology of 
the disease (Faderl et al 1999; Barnes and Melo 2002; Litzow 2006; Quintas-Cardama 
and Cortes 2006). The cytogenetic hallmark of CML is the Philadelphia chromosome 
(Ph), a reciprocal translocation between chromosomes 9 and 22 (t(9; 22)(q34; q11)). 
This translocation is present in 95% of patients with CML (Rowley 1973).
The conjugation of the breakpoint cluster region gene on chromosome 22 and 
the Abelson (Abl) kinase gene on chromosome 9 is a product of unfaithful repair 
of 2 DNA double-strand breaks in genes encoding BCR and ABL that creates 
the chimeric BCR-ABL oncogene, which codes for a deregulated tyrosine kinase 
(Koptyra et al 2006). The 210 kDa Bcr-Abl protein is expressed in CML patients, 
whereas a 190 kDa Bcr-Abl protein, resulting from an alternative breakpoint in the 
BCR gene, is expressed in Ph+ acute lymphoblastic leukaemia (ALL) patients (Chan 
et al 1987).
Bcr-Abl displays transforming activity owing to its constitutive kinase activity, 
which results in multiple signal transduction pathways, including Ras/Raf/
mitogen-activated protein kinase (MAPK), phosphatidylinositol 3 kinase, STAT5/Janus 
kinase, and Myc, leading to uncontrolled cell proliferation and reduced apoptosis and 
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resulting in the malignant expansion of pluripotent stem cells 
in bone marrow (Bhatia et al 2003; Hu et al 2004).
The Bcr-Abl kinase itself enhances genomic instability 
leading to accumulation of secondary genetic errors, which 
may be responsible for resistance to small molecule drugs, 
such as imatinib, and transformation to advanced phases 
(Koptyra et al 2006).
CML normally progresses through 3 clinically recognized 
phases. Approximately 90% of patients are diagnosed 
during the typically indolent chronic phase (CP), which is 
followed by an accelerated phase (AP) and a terminal blastic 
phase (BP).
The criteria for passage into CML-AP and CML-BP 
are defi ned hematologically on the basis of blast cell and 
progenitor cell counts. CML-AP persists for several months 
before the transition into CML-BP, typically defi ned as 
30% blasts in the peripheral blood or bone marrow. Median 
survival in CML-BP is 3 to 6 months. CML-BP can mani-
fest as myeloid, lymphoid, or undifferentiated phenotypes. 
Although progression through all stages is most common, 
20% to 25% of patients progress directly from CP to BP. 
The time course for progression can also be extremely 
varied.
The mechanisms behind CML disease progression are 
not fully understood. As patients progress through the 
different phases, cytogenetic abnormalities may be detected 
in addition to the Ph chromosome (termed clonal evolution). 
Besides the propensity of the Ph-positive clone to acquire 
additional genetic changes, the BCR-ABL gene itself may 
acquire mutations that allow an already genetically unstable 
phenotype to further changes. Furthermore mutations and 
deletions in other specifi c genes may also occur (eg, p53, 
p16/INK4a, and RB). Increasing evidence suggests that Src 
family kinases may be involved in CML disease progression 
through the induction of cytokine independence and apoptotic 
protection (Lionberger et al 2000; Donato et al 2003; Dai 
et al 2004).
One of the major differences between the CP and BP 
of CML is their differential responsiveness to antileukemia 
treatment including tyrosine kinase inhibitors. Whereas 
most patients in CP achieve sustained responses, responses 
in patients with BP are usually transient.
In selected patients, allogeneic stem cell transplantation 
(ASCT), can be curative (Goldman and Melo 2003). Many 
patients, however, are not candidates for ASCT because of 
advanced age, the extent and/or duration of disease, or lack 
of availability of well-matched donors. The curative ability 
of ASCT resides, in part, in a direct graft-versus-leukemia 
effect that has permitted reductions in the intensity of 
ablative chemotherapy and/or substitution of immunosup-
pressive agents, with consequent extension of this treatment 
to patients previously not considered candidates for ASCT. 
Graft-versus-host disease and opportunistic infections cause 
signifi cant mortality and morbidities threatening survival 
after ASCT, particularly in the fi rst 1 to 3 years after the 
transplant.
Because of the high associated mortality rates (10%–20% 
within the fi rst year post treatment) and serious adverse 
events, even in patients with favorable prognostic criteria 
(matched sibling donor, CP disease diagnosed within 1 year 
and 40 years of age), ASCT is considered a salvage 
approach after tyrosine kinase inhibitors therapy failure 
(Quintas-Cardama and Cortes 2006).
Treatment with imatinib
The introduction of imatinib represented a breakthrough 
for CML therapy and for the targeted approach to cancer 
therapy. Imatinib, a small-molecule tyrosine kinase ihibitor 
(TKI), was the fi rst drug to be developed that targets Bcr-Abl 
(Deininger et al 2005). Imatinib binds to the inactive protein 
conformation, partially occluding its ATP-binding site 
(Schindler et al 2000). Thus imatinib prevents the switch to 
the active conformation of Bcr-Abl, thereby blocking signal 
transduction. Imatinib also inhibits other signaling proteins; 
for example, platelet-derived growth factor receptor and 
c-Kit (Buchdunger et al 2000). The effi cacy of imatinib 
against Ph-positive CML was demonstrated in various in 
vitro and in vivo preclinical models (Deininger et al 2005). 
The clinical benefi ts of this drug were subsequently shown 
in numerous clinical trials.
The prospective International Randomized trial of 
Interferon plus cytarabine versus imatinib [STI-571] 
(IRIS) Study of 1106 patients with newly diagnosed 
CML in CP established the superiority of imatinib 
400 mg daily over interferon-alpha and low-dose cytarabine 
(O’Brien et al 2003). The complete hematologic response 
rates were 95% versus 55%; the complete cytogenetic 
response rates were 76% versus 15%; and the progres-
sion-free survival rates at 18 months were 97% versus 
91% (p  0.001). The molecular response rates were 
also signifi cantly better, with estimated major molecular 
response rates at 12 months of 40% versus 2% (O’Brien 
et al 2003).
A 5-year update of the IRIS study continued to show 
positive results (Druker et al 2006). Three hundred and 
eighty-two patients remained on imatinib front-line therapy. 
Drug Design, Development and Therapy 2008:2 235
Nilotinib in chronic myeloid leukemia
The cumulative complete hematologic response, major 
cytogenetic response, and complete cytogenetic response 
rates were 98%, 92%, and 87%, respectively. The estimated 
5-year event-free survival was 83%; only 6.3% of patients 
progressed to accelerated and blastic phases. The overall 
annual progression rate has declined to 0.9% in the fi fth 
year of therapy, compared with 1.5%, 4.8%, and 7.5% in the 
previous 3 years, suggesting that disease progression may 
be diminished in the following years. The estimated 5-year 
survival rate was 89%; excluding non-CML deaths, it was 
95%. The intensity of the cytogenetic response after 12 and 
18 months of imatinib therapy has important implications 
for survival without transformation. The estimated 5-year 
survival rate in patients not achieving a major cytogenetic 
response at 12 months was signifi cantly less (81%) than 
those who achieved major cytogenetic response (complete 
97%, partial 93%; p  0.001). At 18 months of therapy, 
the estimated 5-year survival rate for patients not achieving 
a complete cytogenetic response was significantly less 
than those who achieved complete cytogenetic response 
(99% versus 90%; p  0.001). There was a continuous 
improvement in the rate of molecular response: the rate of 
major molecular response improved from 44% at 1 year to 
68% at 4 years of therapy (Goldman et al 2005). This study 
did not document a survival advantage for imatinib because 
of the crossover design. Studies comparing the survival 
of patients treated with imatinib with historical cohorts 
treated with interferon-alpha-based therapy demonstrated 
the anticipated survival advantage (Kantarjian et al 2003; 
Roy et al 2006) .
Imatinib adverse events
Adverse events (AEs) reported with imatinib are generally 
mild or moderate, and included superfi cial edema (60%), 
nausea (50%), muscle cramps (49%), and rashes (according 
to the common terminology criteria rare version 3.0). 
Grade 3–4 events were uncommon except for neutropenia 
(17%) and thrombocytopenia (9%). Only 4% of patients 
had to discontinue imatinib because of AEs (Druker 
et al 2006).
Resistance to imatinib
Despite the benefi t of imatinib over prior treatments, some 
patients may develop resistance (Shah 2005), with a reported 
annual relapse rate of 1% to 4% in newly diagnosed patients 
in chronic phase with the incidence decreasing over time 
(Hochhaus and Hughes 2004). In fact, during the 4th and 
the 5th year of follow-up on the IRIS trial, less than 1% of 
patients have lost response per year. Multiple mechanisms 
of resistance to imatinib, Bcr-Abl-dependent and Bcr-Abl-
independent, have been identifi ed; one of the best character-
ized is mutations in the Bcr-Abl kinase domain. Mutations 
have been detected in 30% to 50% of patients who develop 
imatinib resistance (Hochhaus et al 2002). Clinically relevant 
mutations disrupt critical contact points between imatinib and 
Bcr-Abl or may favor the active conformation of Bcr-Abl, to 
which imatinib is unable to bind (Deininger et al 2005; Shah 
2005). Numerous Bcr-Abl mutations have been identifi ed. 
Not all mutations have the same biochemical and clinical 
properties: some Bcr-Abl mutations result in a highly resis-
tant phenotype in vitro; others are still relatively sensitive 
to imatinib and resistance may potentially be overcome by a 
dose increase of imatinib (Corbin et al 2002; Hochhaus et al 
2002; Shah et al 2002; von Bubnoff et al 2002; Azam et al 
2003). The T315I mutation and some mutations affecting the 
so-called p-loop of Bcr-Abl confer a greater level of resis-
tance to imatinib and to the novel tyrosine kinase inhibitors 
(Hughes et al 2006; Jabbour et al 2006).
Other mechanisms of imatinib resistance may include: 
increased expression of Bcr-Abl through genomic ampli-
fi cation (Nicolini et al 2006), overexpression of Lyn or 
other Src-family tyrosine kinases (Donato et al 2003; Dai 
et al 2004), or overexpression of drug effl ux proteins such 
as P-glycoprotein, which may decrease the intracellular 
concentration of imatinib in leukemic cells (Thomas et al 
2004). Interestingly, treatment responses correlate with 
plasma concentrations of imatinib, suggesting that insuffi -
cient plasma levels may contribute to imatinib resistance.34 
In addition, clonal evolution may also be involved in imatinib 
resistance through inactivation of the tumor suppressor gene 
p53 (Wendel et al 2006). Strategies to overcome imatinib 
resistance are a logical progression for improving the 
prognosis of patients with CML.
TKIs: The next generation
New TKIs are available or in development that are more 
potent than imatinib for inhibiting Bcr-Abl and have a 
decreased potential for resistance. These include dasatinib 
(Sprycel®; BMS-354825, Bristol-Myers-Squibb), an orally 
bioavailable dual Bcr-Abl and Src inhibitor, and nilotinib 
(Tasigna®; AMN-107, Novartis), a potent selective Bcr-
Abl inhibitor. Both nilotinib and dasatinib induced sig-
nifi cant clinical responses. Dasatinib was approved for 
the treatment of patients with all phase CML or Ph+ ALL 
who are unable to tolerate or have not responded to other 
treatments, including imatinib. Nilotinib was approved 
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for CML patients in chronic and accelerated phases, post 
imatinib failure. Here we review the recent available 
data on nilotinib.
Nilotinib
Preclinical profi le
Nilotinib (formerly AMN107, Novartis Pharmaceuticals, 
Basel, Switzerland) is an oral TKI that was developed 
from its parent compound, imatinib, as a more potent 
inhibitor of Bcr-Abl (Golemovic et al 2005; Verstovsek 
et al 2005). Rational design of novel inhibitors exhibiting 
effectiveness against imatinib-resistant mutants of 
Bcr-Abl was carried out, based on the crystal structure of 
the imatinib-Abl complex. Crystallographic analysis has 
revealed that imatinib binds to and stabilizes an inactive, 
DFG (aspartate-phenylalanine-glycine)-out conformation of 
Abl in which the activation loop is in a “closed” substrate-
mimicking position and there is extensive distortion of the 
ATP binding loop.
The high topological congruency between the aniline-
pyrimidine substructure and the surface of the distorted 
ATP-binding pocket suggest that making changes within this 
region of imatinib might not be very productive. However, 
the methylpiperazinyl group of imatinib lies along a surface-
exposed pocket of the Abl kinase and is potentially more 
amenable to modifi cation. It was hypothesized that the 
potency and selectivity of imatinib could be improved by 
maintaining binding to the inactive conformation of the 
Abl kinase domain, but incorporating alternative binding 
groups to the N-methylpiperazine moiety, while preserving 
an amide pharmacophore to retain H-bond interactions to 
Glu286 and Asp381. Like imatinib, nilotinib binds to the 
inactive conformation of the Abl tyrosine kinase, with p-loop 
folding over the ATP-binding site, and the activation-loop 
(involving the pyridyl-N and the backbone-NH of Met318, 
the anilino-NH and the side-chain hydroxyl of Thr315, the 
amido-NH and side-chain carboxylate of Glu286, as well as 
the amido-C = O and backbone-NH of Asp381) blocking the 
substrate binding site, to disrupt the ATP-phosphate-binding 
site, and inhibit the catalytic activity of the enzyme (Manley 
et al 2005).
This better fi t between nilotinib and the kinase binding 
site, as well as differences in interactions with specifi c amino 
acid residues, led to the development of a high-affi nity 
ATP-competitive inhibitor, 10 to 30 times more potent than 
imatinib, which decreases proliferation and viability of 
wild-type Bcr-Abl- and imatinib-resistant Bcr-Abl mutant-
expressing cells in vitro by selectively inhibiting Bcr-Abl 
autophosphorylation (Schindler et al 2000; Nagar et al 2002; 
Manley et al 2005; Weisberg et al 2005). Nilotinib inhibits 
the kinase activity of most Bcr-Abl mutants, except for T315I 
(also resistant to imatinib and dasatinib) (O’Hare et al 2005). 
Like imatinib, nilotinib does not inhibit Src kinase and does 
not bind to the inactive conformation of Bcr-Abl.
Nilotinib was tested alongside imatinib and dasatinib in 
16 Bcl-Abl mutant cell lines representing 90% of clinical 
isolates. In recombinant kinase assays, IC
50
 values for inhibi-
tion of substrate phosphorylation by wildtype Abl were 280, 
15 and 0.6 nM for imatinib, nilotinib and dasatinib, respec-
tively. A reduced susceptibility of 10-fold compared with 
wild type was seen in 7 mutants with imatinib (3 of which 
were completely insensitive) and 3 with nilotinib (IC
50
 for 
13/16 mutants 160 nM). The activity of dasatinib against 
15 mutants remained between 0.5-fold and 1.5-fold of that 
against wildtype (all IC
50
 values 1.8 nM). Inhibition of the 
proliferation of BaF3 cells expressing the mutant kinases 
followed a similar pattern for the three agents. IC
50
 values 
were higher and more variable for imatinib (480–3475 nM; 
3 mutants completely resistant) and nilotinib (15–450 nM) 
than for dasatinib (0.8–7.4 nM).
Nilotinib inhibits Abl-catalyzed peptide substrate phos-
phorylation with a 20-fold higher potency than imatinib (IC50 
[concentration of inhibitor resulting in a 50% reduction in 
cell viability]: 15 versus 280 nmol/L). Corresponding experi-
ments with mutant Abl kinase domains revealed that a 20-fold 
improved potency of nilotinib compared with imatinib is also 
seen with the imatinib-resistant mutants. A model of nilotinib 
in complex with Abl kinase mutant M351T showed that the 
sensitivity of Bcr-Abl mutants to nilotinib segregates into 
4 categories: high (IC50  70 nmol/L: M244V, G250E, 
Q252H, F3llL, F317L, M351T, V379I, L387M, H396P, 
H396R), medium (IC50  200 nmol/L: Y253F, E255K, 
F359V), low (IC50  450 nmol/L: Y253H, E255V), and 
insensitive (IC50  2 μmol/L: T315I), with the level of 
nilotinib sensitivity at positions 253 and 255 dependent on 
the specifi c amino acid substitution (mutants Y253F and 
E255K fall in the medium classifi cation, whereas Y253H 
and E255V comprise the low category). The mutants, other 
than T315I, that were least responsive to nilotinib in all 
three cellular assays were Y253H and E255V. The pattern 
of resistance to nilotinib and dasatinib differed; those with 
greatest resistance to nilotinib (Y253H and E255V) were 
susceptible to dasatinib. T315I remained resistant to all the 
three drugs.
In vivo experiments with CML xenografts in mice 
demonstrated that nilotinib treatment, compared with 
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treatment with vehicle, improved survival of mice infused 
with either wild type Bcr-Abl or the imatinib-resistant 
Bcr-Abl mutant (E255V) (Golemovic et al 2005; O’Hare 
et al 2005).
Although nilotinib and imatinib exhibit great selectiv-
ity for Bcr-Abl, Kit and Pdgf-R, these agents bind these 
kinases with different affi nities. The ranking of imatinib 
affi nities is Pdgf-R Kit Bcr-Abl, whereas for nilotinib 
this is Bcr-Abl Pdgfr Kit. Nilotinib had no signifi cant 
effect on the variability of proliferation of Ba/F3 cells 
rendered factor-independent through expression of 
several other tyrosine kinases such as ErbB2, Flt3, Met, 
Ret, Igf-1 or Npm-Alk at concentrations 3 μM (Weisberg 
et al 2005).
Nilotinib was also shown to inhibit cell proliferation 
of the KBM5 line, which over expressed Bcr-Abl, with 
IC50 values of 480 nM (Golemovic et al 2005), and to 
revert the expression of the pre-apoptotic protein BCL-2- 
interacting mediator both in vivo and ex vivo (Aichberger 
et al 2005).
In K562, the IC50 of nilotinib was 30 nM versus 
600 nM for IM, consistent with its reported 20-fold-higher 
potency. However, in primary CD34-CML cells, nilotinib 
and imatinib were equipotent for inhibition of Bcr-Abl 
activity. CD34-cells were still able to expand over 72 hours 
with 5 μM of either drug, although there was a concentra-
tion-dependent restriction of amplifi cation. As for imatinib, 
the most primitive cells persisted and accumulated over 
72 hours with nilotinib and remained. Furthermore, nilotinib 
with imatinib led to further accumulation of this population, 
suggesting at least additive anti-proliferative effects. These 
results confi rmed that, like imatinib, the predominant effect 
of nilotinib is antiproliferative rather than proapoptotic 
(Jorgensen et al 2007).
Phase I clinical trial
Nilotinib has shown promise in clinical trials with 
effectiveness in patients whose disease is caused by mutated 
forms of Bcr-Abl that do not respond to imatinib.
In a phase 1 dose-escalation study, nilotinib was evaluated 
in patients with imatinib-resistant CML in various phases or 
with Ph+ ALL (Kantarjian et al 2006).
Nilotinib was administered orally to 119 patients (17 in 
chronic phase disease, 56 in accelerated phase [10 with clonal 
evolution only], 24 in myeloid blast phase, and 9 in lymphoid 
blast phase, together with 13 Ph+ ALL patients), for up to 
385 days. Signifi cant clinical activity was identifi ed in all 
CML phases. Among 12 patients with CML-CP, 11 achieved 
a complete hematologic remission (92%) and 9 of 17 (53%) 
a cytogenetic response (6 complete cytogenetic responses). 
Nilotinib also demonstrated activity against advanced 
disease: of the patients in AP, 38 of 51 (74%) achieved a 
hematologic response, including 26 complete hematologic 
remission, 3 marrow responses and 9 returned to CML-CP; 
31 (55%) had a cytogenetic response including 7 partial 
cytogenetic response and 8 a complete cytogenetic response. 
In BP, the hematologic response rate was 42% for patients 
in myeloid blast phase and 33% for those in lymphoid blast 
phase: among 24 patients with myeloid CML-BP, 2 achieved 
complete hematologic remission and 6 returned to CML-CP; 
among 9 patients with lymphoid CML-BP, 1 achieved a 
marrow response and 2 returned to CML-CP. Seven patients 
with myeloid (29%) and 2 with lymphoid (22%) CML-BP 
achieved a cytogenetic response with nilotinib. One patient 
in each of the two groups achieved a complete cytogenetic 
response. Four patients with myeloid BP achieved a partial 
cytogenetic response (17%). Responses were observed in 
most patients with Bcr-Abl mutants, according to expected 
in vitro data.
The dose levels initially evaluated were 50 to 1200 mg 
once per day. Plasma level saturation was observed at more 
than 400 mg/day. Doses of nilotinib of 400 or 600 mg twice 
daily produced the best responses. Intra-patient dose escala-
tion was permitted in patients with an adequate response and 
no dose-limiting toxicities.
The pharmacokinetics of nilotinib have been evaluated. 
The median time to peak serum concentrations of nilotinib 
was 3 hours and the mean peak concentration at steady state, 
reached by day 8, in patients administered 400 mg twice 
daily was 3.6 μM. Nilotinib had an apparent half-life of 
15 hours (Table 1). Peak concentration and area under the 
serum concentration-time curve at steady state increased 
with dose from 50 to 400 mg and plateaued with doses 
greater than 400 mg. Non-linearity with higher nilotinib 
doses is thought to result from saturation of gastrointestinal 
absorption; dosing nilotinib at 400 mg twice daily resulted in 
steady-state exposure greater than that observed with a single 
daily 800 mg dose. Based on these data, twice daily dosing 
was selected for phase II studies of nilotinib.
The treatment was well tolerated. At the dose of 400 mg 
twice daily, grade 3 or 4 nonhematologic adverse events 
included pruritus (3%), increased total and conjugated (3%) 
as well as unconjugated bilirubin levels (3%), increased 
lipase levels (9%), and increased levels of liver enzymes 
(3%). Most frequent grade 3–4 adverse events were hema-
tologic: the incidence of grade 3 or 4 thrombocytopenia 
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was 25%, and the incidences of grade 3 or 4 anemia and 
neutropenia were less than 10%. Other adverse events were 
less frequent and were primarily grade 1–2. In this study, 
nilotinib was not associated with the edema frequently 
associated with imatinib.
Neutropenia and indirect self-limited reversible 
hyperbilirubinemia were observed mostly at the dose of 
600 mg twice daily. A nilotinib dose of 400 mg twice daily 
was selected for the phase 2 studies based on effi cacy and 
long-term side effects.
Phase 2 clinical trials
Consistent with phase 1 results, results from following 
phase 2 studies have demonstrated activity in all phases 
of disease. Thus, nilotinib has been approved in both the 
US and Europe for the treatment of patients with CML-CP 
and -AP who are resistant or intolerant to prior therapy, 
including imatinib. Three single-arm studies in patients with 
all phases of imatinib-resistant or imatinib-intolerant CML 
or Ph-positive ALL were recently updated (Ottmann et al 
2007; Giles et al 2008; Kantarjian et al 2008; le Coutre et al 
2008) (Table 2).
Intolerance was defi ned as any non-hematologic toxicity 
of grade 3 or higher severity, or of grade 2 or higher severity 
lasting more than 1 month or recurring more than 3 times 
despite dose reduction and maximal supportive care. 
The defi nition of intolerance also included hematologic 
toxicity of grade 4 severity persisting for more than 7 days. 
Imatinib-intolerant patients who had previously demonstrated 
sensitivity to imatinib, as evidenced by a prior major 
cytogenetic response, were to be excluded from participation 
in the studies.
At the time of the report, 321 patients (71% imatinib-
resistant; 21% imatinib-intolerant) with CML-CP treated with 
nilotinib were evaluable (Kantarjian et al 2008). Nilotinib was 
started at 400 mg twice daily (bid), on an empty stomach, and 
escalated to 600 mg bid for inadequate responses. Complete 
hematologic response was reported in 158 of 206 patients 
with active disease at the beginning (77%). Overall, the major 
cytogenetic response rate was 57%; 41% had a complete cyto-
genetic response. Major cytogenetic responses were observed 
in 125 (55%) of the 227 imatinib-resistant patients and in 
59 (63%) of the 94 imatinib-intolerant patients. The median 
time to complete hematologic response and major cytogenetic 
response was 1.0 and 2.8 months, respectively. The majority 
of patients (84%) maintained the major cytogenetic response 
for at least 18 months. At 18 months, the estimated overall 
survival rate was 91%.
One hundred and thirty-six patients with CML-AP 
received at least 1 dose of nilotinib, with a median treatment 
duration of 210 days (le Coutre et al 2008). A confi rmed 
hematologic response occurred in 69/129 patients (54%); 
26% had a complete hematologic response. Major cyto-
genetic responses occurred in 40/129 patients (31%); 
24/129 patients (19%) had complete cytogenetic responses. 
Thirty out of 104 patients (29%) of imatinib-resistant patients 
and 10/25 imatinib-intolerant patients (40%), had a major 
cytogenetic response. Time to fi rst hematologic response 
and major cytogenetic response was 1 and 2.8 months, 
respectively. At 12 months, it was estimated that 57% of 
patients were without progression and the estimated overall 
survival rate was 81%.
One hundred and thirty-six patients with CML-BP 
(myeloid, n = 105; lymphoid, n = 31) were treated with 
nilotinib 400 mg twice daily (Giles et al 2008). The 
hematologic response rate was 21% and 11% achieved com-
plete hematologic response. Major cytogenetic response was 
achieved in 55 patients (40%), and 40 (29%) had complete 
cytogenetic response. Overall survival at 12 months was 
42%. Treatment with nilotinib is ongoing in 13 patients 
(10%). More than half of patients discontinued treatment 
due to disease progression.
In all three studies, nilotinib was well tolerated. 
The toxicity profi le was consistent with the phase 1 study, 
Table 1 Phase 2 data for nilotinib second-line to imatinib failure
Disease N % Response
Cytogenetic 
response
CHR Major Complete Overall survival
CML 
chronic
321 77 57 41 91% (18 months)
CML 
accelerated
136 26 31 19 81% (12 months)
CML blastic 136 11 40 29 42% (12 months)
Abbreviations: CHR, complete hematologic response; CML, chronic myeloid leukemia; 
ALL, acute lymphoid leukemia; Ph, Philadelphia chromosome.
Table 2 Pharmacokinetics (Nilotinib 2008)
Route and formulation Oral: 200 mg caps
Absorption Tmax 3 hours
Plasma half-life 15–17 hours
Metabolism By CYP 3A4, through oxidation 
and hydroxilation
Excretion Mostly in feces
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with generally low and manageable rates of severe adverse 
events. The rate of grade 3–4 neutropenia was 30% in CP, 
39% in AP, and 67% in BP. The rate of grade 3–4 throm-
bocytopenia was 28% in CP, 41% in AP, and 62% in BP. 
Non-hematologic side effects were infrequent and were usu-
ally grade 1–2. These included fatigue, pruritus, headache, 
muscle spasms, and gastrointestinal disturbances. Grade 3–4 
non-hematologic adverse events were rare and included rash, 
headache, diarrhea, nausea, and fatigue. Transient self-lim-
ited elevations of indirect bilirubin were noted. One patient 
had sudden cardiac death. A low incidence of QT prolonga-
tion (QTcF 500 msec, 1%) was observed overall.
These reports suggest that nilotinib may provide a 
safe and effective treatment option for CML. There was 
minimal cross intolerance between imatinib and nilotinib 
(Jabbour et al 2008). Nilotinib was associated with less fl uid 
retention, edema, cramps, and weight gain, or with pleural 
effusions.
Front-line therapy
As seen with imatinib resistance in CML, cancer cells have 
the capacity to mutate and acquire properties that enable 
them to develop resistance to treatment. As a signifi cant 
proportion of patients are/become resistant to imatinib, earlier 
use of nilotinib (ie, as a front-line therapy) in all phases of 
CML may be benefi cial in 2 potential ways: by promoting 
an early response, thereby potentially improving prognosis; 
and/or by avoiding the development of treatment resistance. 
The clinical challenge in this setting would be to accurately 
identify patients who are likely to fail imatinib treatment by 
using clinical risk factors and genetic testing as predictive 
factors.
A phase 2 study in patients with newly diagnosed 
CML-CP showed that nilotinib 400 mg twice daily induces 
a complete cytogenetic response in nearly all patients as 
early as 3 months after the start of therapy with a favorable 
toxicity profi le. Thirty-fi ve patients have been treated for 
a median of 6.5 months. Complete cytogenetic responses 
were achieved, respectively, by 96% and by 100% of 
patients at 3- and 6-month evaluations. The rate of complete 
cytogenetic response at 3, 6 and 12 months compares favor-
ably to those observed in historical controls treated with 
imatinib 400 mg or 800 mg daily: at 12 months 100% of 
patients were still in response. Major molecular response 
was observed in 13% at 3 months, 45% at 6 months and 
45% at 12 months. Nilotinib showed generally low and 
manageable rates of grades 3–4 adverse events (Cortes 
et al 2008).
Potential resistance to second 
generation TKIs
As clinical experience with second generation TKIs grows, 
it is becoming clear that patients can also relapse on treat-
ment after an initial response, particularly in the setting of 
advanced-phase CML. Although over expression of Bcr-Abl 
is a possible resistance mechanism for nilotinib (Mahon et al 
2004), resistance is more likely to arise through the emer-
gence of clones expressing nilotinib-resistant mutant forms 
of Bcr-Abl. With the increased use of these newer TKIs, 
it has been suggested that the spectrum of kinase domain 
mutations may change. As these compounds enter the clinical 
arena, it would be useful to predict the profi le of mutations 
that confer drug resistance because this would allow for a 
rational approach to the design of combination strategies. 
Experimental models of in vitro drug sensitivity exposing 
Bcr-Abl-expressing cells to nilotinib or dasatinib under con-
ditions that favor the development of mutations have shown 
that although their mutagenic potential is lower than that of 
imatinib, mutations may still emerge (Table 3).
Table 3 In vitro mutagenesis for resistance to nilotinib
Von Bubnoff et al53 Bradeen et al52 Ray et al54
K247N
L248V L248V
G250E
Q252H Q252H
Y253C
Y253H Y253H Y253H
E255K E255K E255K
E255V E255V
L273F
E282K
K285N
V289L
E292K
E292V
N297T
F311I
T315I T315I T315I
S349L
F359C
F359I
F359V
H375P
L384M
L387F
T406I
W470L
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In a cell-line-based mutagenesis study, the emergence 
of Bcr-Abl mutations resistant to imatinib, nilotinib and 
dasatinib were compared: 20 different mutations were 
identifi ed with imatinib mesylate, 10 with nilotinib (including 
only 1 novel mutation, E292V) and 9 with dasatinib. 
In contrast to imatinib mesylate, mutations recovered in 
the presence of 50 nM nilotinib were limited to L248V, 
G250E, Y253H, E255K (p-loop), T315I, F359C, L384M 
and L387F. One novel mutation (E292V) was seen in a 
single clone at 50 nM. At 500 nM, only Y253H, E255V 
and T315I were detected, in line with their reported level of 
resistance in cell proliferation assays. At concentrations of 
at least 2000 nM, only T315I was recovered. The fact that 
only 1 novel mutation occurred at a low concentration and 
the lack of novel, previously undescribed mutations at inter-
mediate inhibitor concentrations (500 nM) suggests that the 
structural modifi cations of nilotinib compared with imatinib 
do not generate clinically relevant novel vulnerable sites. 
Because the plasma trough concentrations at the maximum 
tolerated dose (MTD) of nilotinib (400 mg twice daily) are in 
the range of 2000 nM, the prediction is that only T315I will 
emerge in patients treated with the MTD. Interestingly, with 
combination of nilotinib plus other TKIs such as imatinib or 
dasatinib, maximal suppression of resistant clone outgrowth 
was achieved with lower concentrations compared with 
single agents (Bradeen et al 2006).
An alternative cell-based screening assay designed to 
predict such mutations has recently been applied to nilotinib 
(von Bubnoff et al 2006). Using this system, a reduced pattern 
of mutations was observed for nilotinib, having some overlap 
with that seen for imatinib: Q252H, Y253H, E255K(V), 
F311I, T315I, S349L and F359I(V), all of which, with the 
exception of the T315I mutant, were suppressed at clinically 
achievable concentrations of nilotinib.
Bcr-Abl point mutations conferring resistance to nilotinib 
have also been identifi ed in a random mutagenesis study (Ray 
et al 2005). In this study, 11 novel mutations were detected 
(K247N, L248V, L273F, E282K, K285N, V289L, E292K, 
N297T, H375P, T406I and W430L), in addition to 5 (Q252H, 
Y253C (H), E255K and T315I), which have been previously 
observed in CML patients treated with imatinib. Although 
these studies do not consistently identify the same drug-
resistant Bcr-Abl point mutations for individual drugs, it is 
clear that all 3 compounds display different mutagenicity 
profi les.
The patterns of mutations occurring in patients with 
all phase CML treated sequentially with imatinib, and 
1 or 2 second-generation TKIs after imatinib failure were 
investigated (Cortes et al 2007). Response rates were similar 
for patients with and without mutations, regardless of muta-
tion site except for T315I. Acquisition of kinase domain 
mutations was the most frequently identifi ed mechanism 
of resistance for patients who failed a second-generation 
TKI therapy. The codons involved were diverse, and most 
frequently included those also seen after imatinib failure. 
However, some mutations occurred more frequently after 
specifi c second TKIs, such as F317L after dasatinib, and 
certain p-loop mutations after nilotinib. Few novel muta-
tions also emerged, such as V299L after dasatinib, and in 
some instances they did not confer resistance to imatinib. 
An increase in the frequency of T315I was not observed. 
The spectrum of mutations that emerged following therapy 
with second TKIs was compared to those that developed 
in previously published in vitro mutagenesis models. The 
mutations that persisted or developed following switch 
to new TKI were at sites also found in prior in vitro TKI 
mutagenesis assays.
Mutation regression/acquisition/persistence generally 
refl ected the in vitro differential sensitivity predicted for each 
TKI. The mutations emerging after nilotinib and dasatinib 
also correlate to some extent with those that had the least 
in vitro sensitivity to these agents.
Preliminary analysis from phase 2 studies suggested 
that levels of response to new TKIs depend on the type 
of Bcr-Abl kinase domain mutation. Specifi cally, patients 
harboring native Bcr-Abl and patients with a sensitive 
mutation had comparable response rates, whereas patients 
with mutations that confer intermediate sensitivity in vitro 
exhibited lower rates of major cytogenetic response. The 
clinical response of BCR-ABL with particular mutations 
has been modeled by classifying each mutation based on 
the in vitro IC
50
 for each drug against kinase activity for 
Bcr-Abl with that mutation into high-, intermediate- and 
low-sensitivity groups. Mutation sensitivity was defi ned 
by the IC
50
 value: IC
50
 values were 3 , 60 and 60 nM 
for dasatinib, and 50, 500 and 500 nM for nilotinib 
(O’Hare et al 2007a) (Table 4). Investigating whether in vitro 
sensitivity of kinase domain mutation correlates with out-
come of patients receiving second generation TKI, it was 
found that the outcome depends on the type of mutation, with 
mutations with predicted intermediate levels of sensitivity 
having decreased probability of response and event free 
survival, particularly in CP. The correlation with IC
50
 was 
less evident in advanced phases suggesting more complex 
mechanisms of resistance. In the same line, overall survival 
of patients with T315I mutations was mostly found to be 
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dependent on the stage of the disease (Jabbour et al 2007a). 
If this preliminary observation holds, rational decisions on 
drug and dose may require consideration of mutation type. 
In patients failing a TKI in whom a mutation with interme-
diate in vitro sensitivity to this agent is detected, change to 
an agent with better in vitro potency against such mutation 
may improve the response (Jabbour et al 2007b). The setting 
for outgrowth of different mutations and their subsequent 
response to different TKIs varies signifi cantly. For example, 
mutations in codon 317, which impairs dasatinib binding, 
have been generated during in vitro mutagenesis with dasat-
inib but not nilotinib, and the F317L, in particular, has been 
reported following treatment with dasatinib. TKIs show-
ing differential in vitro activity against this mutation, like 
nilotinib, may represent the best option for F317L-mutated 
tumors (Jabbour et al 2007c).
Combination therapy
There is growing interest in testing the hypothesis that admin-
istration of multiple Abl kinase inhibitors in early-phase 
patients, could be used to delay or prevent the emergence 
of drug-resistant clones (Shah et al 2005). The combination 
of 2 agents targeting different pathways involved in CML 
may signifi cantly improve response rates and potentially 
increase survival.
Support for this concept is provided by preliminary 
preclinical investigations of the imatinib–nilotinib combi-
nation (Weisberg et al 2007). Additive/synergistic toxicity 
against both imatinib-sensitive and imatinib-resistant 
Bcr-Abl-expressing cells has been reported following 
coadministration of nilotinib and imatinib, in vitro and 
in vivo (Griffi n and Weisberg 2005; Weisberg et al 2005; 
Weisberg et al 2007).
This cooperative activity could result from pharmacody-
namic interactions with cell transporters. Preliminary data 
suggest that synergy between imatinib and nilotinib may 
occur at the level of the CML stem cell due to the ability 
of both imatinib and nilotinib to inhibit or act as substrates 
of the multidrug effl ux transporter Abcg2, which confers 
resistance toward several anticancer drugs (Brendel et al 
2007). It is also reported that imatinib and nilotinib might be 
taken up in cells by different mechanisms, with the infl ux, 
intracellular concentrations of imatinib, and consequently 
patient sensitivity to imatinib depending upon the organic 
cation transporter Oct-1, whereas nilotinib transport appears 
to be independent of Oct-1 (White et al 2006).
Both nilotinib and dasatinib effi ciently block Bcr-Abl 
tyrosine kinase catalytic activity by binding to distinct, 
partially overlapping sites in the kinase domain. Cross resis-
tance with dasatinib is limited to T315I, which is also the only 
mutant isolated at drug concentrations equivalent to maximal 
achievable plasma trough levels (O’Hare et al 2005). With 
drug combinations maximal suppression of resistant clone 
outgrowth was achieved at lower concentrations compared 
with single agents, suggesting that such combinations may 
be equipotent to higher dose single agents. A combination 
of low doses of dasatinib and low doses of nilotinib may 
effectively suppress the emergence of mutations other than 
T315I with an acceptable safety profi le (Talpaz et al 2006; 
Jabbour et al 2007d). This approach needs to be eventually 
extended to include specifi c inhibitors of T315I Bcr-Abl 
kinase domain mutations. Alternatively, it is also important 
to explore the potential for synergy between nilotinib and 
other classes of inhibitors that work through mechanisms not 
involving inhibition of Abl tyrosine kinase activity (Fiskus 
et al 2006; O’Hare et al 2007b; O’Hare et al 2008).
Conclusion
The development of imatinib and subsequent studies into 
mechanisms of imatinib resistance have intensified the 
development of additional treatments for CML. Targeted 
agents have signifi cantly improved the prognosis in CML. 
Further optimization of treatment responses may require 
patient-specifi c therapy based on an evaluation of disease 
characteristics.
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